B cells recognise a target and can develop into cells that make large amounts of antibody. A cell's presence tells you little about what its antibody recognises or whether it helps against a cancer.
A developing B cell assembles an antigen-receptor sequence by V(D)J recombination. Its B-cell receptor contains membrane-bound immunoglobulin and recognises an accessible molecular feature, unlike a conventional T-cell receptor, which recognises peptide held by HLA. Recognition and activation are separate steps. For many protein antigens B cells receive help from suitable CD4 T cells and can internalise recognised material and present fragments to those helpers, while other antigen contexts support responses with less direct T-cell help.
An activated response can leave memory B cells and antibody-secreting cells. A plasmablast is an early antibody-secreting stage that can still divide; plasma cells are further specialised for secretion, some short-lived and some persisting in supportive tissue niches. Memory B cells are not simply plasma cells waiting to secrete. Shapiro-Shelef et al. (2003) deleted the gene for Blimp-1 (prdm1) in mouse B cells: B-cell development and the number of antigen-responding B cells looked normal, yet serum immunoglobulin, short-lived plasma cells, post-germinal-centre plasma cells and memory-response plasma cells were virtually absent, so responding to antigen was not enough for normal secretion. This is a mechanistic mouse experiment, not a human tumour biomarker rule. Some responses pass through germinal centres, where B-cell variants undergo selection; class switching changes antibody class and sequence changes with selection can alter binding quality, which are different processes.
In tumour samples, B cells can present material, supply signals and make antibody, and plasma cells can contribute a large share of immunoglobulin RNA, so a high immunoglobulin signal does not show that cancer cells made it. Neither more B cells nor more antibody is a universal benefit rule; B cells may sit in tertiary lymphoid structures. Flow cytometry and spatial staining distinguish populations by marker combinations that change with differentiation, so a panel for ordinary B cells can miss plasma cells; keep the phenotype definition and the denominator. RNA can show an antibody-production programme or receptor sequence and serum assays measure concentration and class, but what an antibody recognises needs antigen-specific binding and functional tests. Plasma cells are cells, not blood plasma, which is the fluid part of blood.
Shares B cell, Antibody and the tag education-immunology-2026-11.
Shares Antibody and the tag education-immunology-2026-11.
Shares Antibody and the tag education-immunology-2026-11.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/